Halozyme Therapeutics Yönetim
Yönetim kriter kontrolleri 2/4
Halozyme Therapeutics CEO'su Helen Torley, Jan2014 tarihinde atandı, in görev süresi 10.83 yıldır. in toplam yıllık tazminatı $ 11.82M olup, şirket hissesi ve opsiyonları dahil olmak üzere 7.8% maaş ve 92.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.53% ine doğrudan sahiptir ve bu hisseler $ 30.97M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 10.8 yıldır.
Anahtar bilgiler
Helen Torley
İcra Kurulu Başkanı
US$11.8m
Toplam tazminat
| CEO maaş yüzdesi | 7.8% |
| CEO görev süresi | 10.8yrs |
| CEO sahipliği | 0.5% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 10.8yrs |
Son yönetim güncellemeleri
Recent updates
Halozyme: Fabless Or Not, The Stock Is Now A Steal On Evotec Deal
Nov 20Halozyme: Looking For More Growth Following Record Q3 Earnings
Nov 05Not Many Are Piling Into Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Yet
Oct 29
Halozyme Therapeutics: Behind The Pullback
Oct 22Halozyme Therapeutics, Inc.: Significantly Undervalued Growth Based On Current Fundamentals
Aug 14Halozyme Therapeutics (NASDAQ:HALO) Has A Rock Solid Balance Sheet
Aug 13Halozyme Therapeutics, Inc. (NASDAQ:HALO) Not Flying Under The Radar
Jul 17Halozyme Therapeutics: The Story Brightens
Jun 07Is Halozyme Therapeutics (NASDAQ:HALO) Using Too Much Debt?
Apr 26Halozyme's Strategic Partnerships Fueling Next-Gen Therapeutics
Apr 10Does Halozyme Therapeutics (NASDAQ:HALO) Deserve A Spot On Your Watchlist?
Apr 05Halozyme Therapeutics, Inc. (NASDAQ:HALO) Doing What It Can To Lift Shares
Mar 15Earnings Update: Halozyme Therapeutics, Inc. (NASDAQ:HALO) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts
Feb 23Halozyme Therapeutics: A Reasonable Value In An Overvalued Market
Jan 26These 4 Measures Indicate That Halozyme Therapeutics (NASDAQ:HALO) Is Using Debt Safely
Jan 10Halozyme Therapeutics, Inc.'s (NASDAQ:HALO) Intrinsic Value Is Potentially 97% Above Its Share Price
Dec 14Is Halozyme Therapeutics (NASDAQ:HALO) A Risky Investment?
Sep 22Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jul 04We Think Halozyme Therapeutics (NASDAQ:HALO) Can Stay On Top Of Its Debt
May 09Are Investors Undervaluing Halozyme Therapeutics, Inc. (NASDAQ:HALO) By 38%?
Mar 28CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$392m |
| Jun 30 2024 | n/a | n/a | US$337m |
| Mar 31 2024 | n/a | n/a | US$319m |
| Dec 31 2023 | US$12m | US$920k | US$282m |
| Sep 30 2023 | n/a | n/a | US$254m |
| Jun 30 2023 | n/a | n/a | US$234m |
| Mar 31 2023 | n/a | n/a | US$182m |
| Dec 31 2022 | US$10m | US$872k | US$202m |
| Sep 30 2022 | n/a | n/a | US$211m |
| Jun 30 2022 | n/a | n/a | US$366m |
| Mar 31 2022 | n/a | n/a | US$435m |
| Dec 31 2021 | US$7m | US$830k | US$403m |
| Sep 30 2021 | n/a | n/a | US$409m |
| Jun 30 2021 | n/a | n/a | US$229m |
| Mar 31 2021 | n/a | n/a | US$163m |
| Dec 31 2020 | US$7m | US$791k | US$129m |
| Sep 30 2020 | n/a | n/a | US$22m |
| Jun 30 2020 | n/a | n/a | -US$40m |
| Mar 31 2020 | n/a | n/a | -US$80m |
| Dec 31 2019 | US$6m | US$761k | -US$72m |
| Sep 30 2019 | n/a | n/a | -US$40m |
| Jun 30 2019 | n/a | n/a | -US$43m |
| Mar 31 2019 | n/a | n/a | -US$51m |
| Dec 31 2018 | US$6m | US$725k | -US$80m |
| Sep 30 2018 | n/a | n/a | US$46m |
| Jun 30 2018 | n/a | n/a | US$76m |
| Mar 31 2018 | n/a | n/a | US$68m |
| Dec 31 2017 | US$5m | US$671k | US$63m |
Tazminat ve Piyasa: Helen 'nin toplam tazminatı ($USD 11.82M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 7.94M ).
Tazminat ve Kazançlar: Helen 'in maaşı son bir yılda %20'den fazla arttı.
CEO
Helen Torley (61 yo)
10.8yrs
Görev süresi
US$11,820,858
Tazminat
Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. He serves as President, CEO & Director at Halozyme, Inc. Prio...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 10.8yrs | US$11.82m | 0.53% $ 31.0m | |
| Senior VP & CFO | 2.8yrs | US$3.85m | 0.012% $ 708.5k | |
| Senior VP & CTO | no data | US$3.24m | 0.14% $ 8.0m | |
| Senior VP & Chief Legal Officer | 2.8yrs | US$3.61m | 0.0092% $ 534.5k | |
| Chief Operations Officer | 1.1yrs | Veri yok | Veri yok | |
| Head of Investor Relations & Corporate Communications | 2.8yrs | Veri yok | Veri yok | |
| Chief Human Resources Officer | 4.8yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | 1.5yrs | Veri yok | Veri yok | |
| Chief Business Officer | 1.3yrs | Veri yok | Veri yok | |
| Chief Medical Officer | less than a year | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
60yo
Ortalama Yaş
Deneyimli Yönetim: HALO 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| President | 10.8yrs | US$11.82m | 0.53% $ 31.0m | |
| Independent Director | 18.3yrs | US$460.02k | 0.15% $ 8.6m | |
| Independent Chair of the Board | 9.3yrs | US$555.02k | 0.037% $ 2.2m | |
| Member of the Scientific Advisory Board | 20.3yrs | Veri yok | Veri yok | |
| Independent Director | 1.8yrs | US$528.15k | Veri yok | |
| Member of the Advisory Board | no data | Veri yok | Veri yok | |
| Chairman of Scientific Advisory Board | 10.8yrs | US$68.17k | Veri yok | |
| Member of Scientific Advisory Board | 20.4yrs | Veri yok | Veri yok | |
| Member of Scientific Advisory Board | 19.3yrs | Veri yok | Veri yok | |
| Independent Director | 11.7yrs | US$471.83k | 0.039% $ 2.2m | |
| Independent Director | 2.7yrs | US$455.02k | 0.011% $ 653.2k | |
| Independent Director | 6.2yrs | US$470.02k | 0.032% $ 1.8m |
10.8yrs
Ortalama Görev Süresi
66yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: HALO 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.8 yıldır).